TCL Archive Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable January 31, 2003
TCL Archive In Brief: Armitage Appointed to NCAB; UT Board Approves New Clinical Building for MDACC May 19, 2000